Skip to main content

18-02-2021 | ASCO GU 2021 | Conference coverage | Video

Cabozantinib–nivolumab and ipilimumab combinations show potential for GU cancers

Andrea Apolo presents the final analysis of a phase 1 study of cabozantinib plus nivolumab, with or without ipilimumab, which has informed later-phase trials in various metastatic genitourinary malignancies, including rare tumor types (3:31).

Read transcript

Image Credits